Moshe Arkin

Mr. Moshe Arkin has served as Chairman of Sol-Gel’s Board of Directors since 2014. Mr. Arkin currently sits on the board of directors of several private pharmaceutical and medical device companies, including Exalenz Bioscience Ltd., a developer of advanced systems for gastrointestinal and liver disorders since 2006, SoniVie Ltd., a company developing systems for the treatment of pulmonary arterial hypertension, Digma Medical, a company developing systems to treat insulin resistance present in type 2 diabetes and other metabolic syndrome diseases, and Valcare Medical, a company developing heart valve devices.

From 2005 to 2008, Mr. Arkin served as the Head of Generics at Perrigo Company, and from 2005 until 2011, he served as the Vice Chairman of the Board of Directors of Perrigo Company. Prior to joining Sol-Gel, Mr. Arkin served as a director of cCAM Biotherapeutics Ltd., a company focused on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck & Co., Inc. Mr. Arkin served as chairman of Agis Industries Ltd. from its inception in 1972 until its acquisition by Perrigo Company in 2005.

Mr. Arkin holds a BA in psychology from the Tel Aviv University, Israel.